G4 Therapeutics develops first-in-class small molecules that selectively bind G-quadruplex DNA structures — non-canonical genomic elements driving oncogenesis across solid tumour indications.
基世生物医药开发一类全新小分子化合物，选择性结合G四联体DNA结构，靶向驱动实体肿瘤发生的非规范基因组元件。
G-quadruplex (G4) DNA structures form in guanine-rich regions of the genome — particularly at telomeres and oncogene promoters including c-MYC, KRAS, and BCL2. Unlike conventional B-form duplex DNA, G4s are four-stranded architectures stabilised by Hoogsteen hydrogen bonding and central monovalent cations. Stabilising these structures suppresses oncogene transcription — a mechanism orthogonal to all current targeted therapies.
G四联体（G4）DNA结构形成于基因组富含鸟嘌呤的区域，尤其集中于端粒及癌基因启动子（包括c-MYC、KRAS和BCL2）。与传统B型双链DNA不同，G4是由Hoogsteen氢键和中心一价阳离子稳定的四链结构。稳定G4结构可抑制癌基因转录，其作用机制与现有所有靶向疗法完全正交。
High structural selectivity for G4 over duplex DNA, minimising off-target binding对G4结构的高选择性，最大程度减少脱靶结合
Transcriptional suppression via G4 stabilisation at oncogene promoters通过稳定癌基因启动子G4结构抑制转录表达
Favourable physicochemical and pharmacokinetic properties for clinical development具备良好的理化性质和药代动力学特性
Preclinical proof-of-concept across multiple solid tumour models at UCLUCL多项实体肿瘤模型中已完成临床前概念验证
Our lead asset QN-302 targets G-quadruplex structures in oncogene promoters, with solid tumour indications as the initial development focus.
先导化合物QN-302靶向癌基因启动子中的G四联体结构，以实体肿瘤适应症为初期开发重点。
G4 Therapeutics — 基世生物医药（上海）有限公司 — is a Shanghai-registered biotech spinout from UCL's School of Pharmacy. We combine world-leading academic expertise in G-quadruplex biology with agile China-anchored operations and clinical access.
基世生物医药（上海）有限公司是从伦敦大学学院药学院孵化的上海注册生物技术公司。我们将国际顶尖的G四联体研究专业知识与中国本土的灵活运营和临床资源有机结合。
Emeritus Professor, UCL School of Pharmacy. Pioneer of G-quadruplex structural biology and drug discovery with over 30 years dedicated to establishing G4s as druggable oncology targets.
伦敦大学学院药学院荣休教授，G四联体结构生物学与药物发现领域的开拓者，三十余年专注于建立G4靶点的成药研究体系。
PhD, UCL School of Pharmacy. Leads all China-based operations, regulatory strategy, and business development — bridging UCL scientific excellence with Shanghai's biotech ecosystem.
伦敦大学学院药学院博士，负责全部中国区运营、法规策略及商务拓展，连接UCL科研优势与上海生物医药生态系统。
QN-302 was developed and characterised at UCL School of Pharmacy. Our scientific programme builds on intellectual property and expertise accumulated over more than a decade of dedicated G4 drug discovery research.
QN-302在伦敦大学学院药学院开发并完成表征。我们的科学项目基于十余年G4药物发现研究积累的知识产权与专业能力。
We pursue a licensing and co-development model, leveraging China's clinical access advantage while building regulatory-compliant operations. Our near-term focus is IND-enabling studies for QN-302 in priority solid tumour indications.
我们采用许可与联合开发模式，充分利用中国的临床资源优势，同时构建合规运营体系。近期重点是在优先实体肿瘤适应症中推进QN-302的IND申报前研究。
基世生物医药（上海）有限公司
2/F, Area A, 420 Fenglin Road
Xuhui District, Shanghai, PRC
基世生物医药（上海）有限公司
上海市徐汇区枫林路420号2层A区
We welcome discussions with clinical partners, investors, and pharmaceutical companies interested in the G4 oncology space. Our pipeline is designed for partnership at multiple development stages.
我们欢迎与临床合作方、投资机构及对G4肿瘤领域感兴趣的制药企业开展合作洽谈，管线项目支持多阶段合作模式。
We are actively seeking licensing partners, CRO collaborators, and investors aligned with our G4 oncology programme.
我们正积极寻求许可合作伙伴、CRO合作机构及与G4肿瘤项目方向一致的投资方。
Reach Out立即联系
2/F, Area A, 420 Fenglin Road
Xuhui District, Shanghai
上海市徐汇区枫林路420号2层A区
UCL School of Pharmacy
London, United Kingdom
伦敦大学学院药学院
英国伦敦